Revenue grew 224% year-over-year in Q2 Fiscal 2026 to $382,755, and 428% year-over-year on a six-month basis to $762,775, with gross margin expanding to 70.4% First reporting period as a standalone pu ...
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results